Recent Clinical Evidence on EPA and DHA for CV Risk Reduction: Clinical Considerations (Sponsored Satellite Program)

Learning Objectives:

• Attendees of this presentation will be able to: 1. Discuss results from meta-analyses of randomized controlled trials examining the effects of omega-3 fatty acids on cardiovascular disease • Study design limitations • Predictions in 2018
• 2. Describe clinical trial evidence on eicosapentaenoic acid (EPA) and docosahexaenoic acid for cardiovascular risk reduction • Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS) • Reduction of Cardiovascular Events with Icosapent Ethyl--Intervention Trial (REDUCE-IT) • Outcomes Study to Assess Statin Residual Risk Reduction with Epanova in High CV Risk Patients with Hypertriglyceridemia (STRENGTH)
• 3. Apply clinical recommendations for use of EPA • National Lipid Association recommendations • Food and Drug Administration approved indication